# A Clinical Study of HX111 in Patients With Advanced Solid Tumor and Lymphoma

> **NCT07333469** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Hanx Biopharmaceuticals (Wuhan) Co., Ltd.** · enrollment: 70 (estimated)

## Conditions studied

- Solid Tumor and Lymphoma

## Interventions

- **DRUG:** HX111 for injection

## Key facts

- **NCT ID:** NCT07333469
- **Lead sponsor:** Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-19
- **Primary completion:** 2028-01-19
- **Final completion:** 2030-01-19
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07333469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07333469, "A Clinical Study of HX111 in Patients With Advanced Solid Tumor and Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07333469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*